ACTRN12622001243707已完成4 期
Efficacy and safety of artemether- lumefantrine and artesunate - amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mainland Tanzania
ational Institute for Medical Research0 个研究点目标入组 176 人开始时间: 2022年9月14日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 176
研究概览
简要总结
One hundred seventy six patients (88 for artemether-lumefantrine and 88 for artesunate-amodiaquine)) infected with P. falciparum were recruited. The follow-up of patients has recently been completed. Quality control of parasite count and molecular analysis are also being planned.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 6 Months 至 10 Years（—）
- 性别
- All
入选标准
- •age from six months to 10 years
- •malaria Rapid Diagnostic Test (mRDT) positive
- •mono-infection with P. falciparum confirmed by positive blood smear (i.e. no mixed infection);
- •parasitaemia of 500–200,000 per micrometer asexual forms;
- •Presence of axillary or tympanic temperature greater or equal to 37.5 degrees centigrade or history of fever during the past 24 h;;
- •ability to swallow oral medication;
- •ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- •informed consent from parent or guardian.
排除标准
- •presence of general danger signs in children aged between 6 months and 10 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);
- •mRDT negative results
- •weight under 5 kg;
- •haemoglobin below 8 g per dl;
- •mixed or mono-infection with another Plasmodium species detected by microscopy;
- •presence of severe malnutrition defined as a child who has symmetrical oedema involving at least the feet or has a mid-upper arm circumference below 110 mm in children greater or equal 59 months; or BMI of below 16 in children aged 5 years and above)
- •presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- •regular medication, which may interfere with antimalarial pharmacokinetics;
- •history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
研究者
相似试验
已完成
4 期
Efficacy and safety of artemether-lumefantrine (AL) combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in 4 Tribal dominating states in India: Madhya Pradesh, Maharashtra, Chhattisgarh and OdishaInfection - Studies of infection and infectious agentsMalariaACTRN12616001478404Indian Council of Medical Research, (ICMR) Ministry of Health & Family welfare.352
尚未招募
不适用
Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in AngolaInfection - Studies of infection and infectious agentsMalariaACTRN12615000107527Ministry of Health600
已完成
4 期
Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine among children 6 to 59 months for the treatment of uncomplicated Plasmodium falciparum in ChadInfection - Studies of infection and infectious agentsMalariaACTRN12622001476729Ministry of Public Health215
已完成
4 期
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Al Tor Bin Qais in Hajah, Yemen.Infection - Studies of infection and infectious agentsMalariaACTRN12624000526572The Ministry of Public Health and Population88
招募中
4 期
Efficacy and safety of artemether+lumefantrine & dihydroartemisinin+piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in different sentinel site in SudaMalariaACTRN12617000276358Federal Ministry of Health440